Laura Shawver (Silverback Therapeutics)
A longtime Laura Shawver fan calls the serial entrepreneur back to the helm of a biotech upstart
Just a few months after nabbing an $88 million windfall in her payout for Sanofi’s $2.5 billion Synthorx buyout, serial biotech entrepreneur Laura Shawver is back at the helm of another startup.
Seattle-based Silverback Therapeutics recruited Shawver to head the team, just weeks after founding CEO — and OrbiMed partner — Peter Thompson was heralding a $78 million raise to fund their work on a next-gen antibody drug conjugate. Now Shawver will be in charge of steering that program to the clinic, where it will be tested in HER2 positive cancers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
